Kymera Therapeutics Shared New Data Demonstrating That Its Oncology Programs KT-333 & KT-413 Continue To Demonstrate Robust Dose-dependent Target Knockdown In Ongoing Phase 1A Dose Escalation Trials, With No Dose-limiting Toxicities Observed
Portfolio Pulse from Benzinga Newsdesk
Kymera Therapeutics announced new data showing that its oncology programs KT-333 and KT-413 continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1A dose escalation trials, with no dose-limiting toxicities observed.
June 14, 2023 | 8:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kymera Therapeutics' oncology programs KT-333 and KT-413 show promising results in Phase 1A trials, potentially boosting investor confidence in the company.
The positive results from Kymera Therapeutics' ongoing Phase 1A dose escalation trials for its oncology programs KT-333 and KT-413 indicate that the company is making progress in its drug development. This could lead to increased investor confidence in the company's potential for success, which may positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100